TARRYTOWN, N.Y., April 18, 2012 /PRNewswire/ -- Bayer HealthCare today announced that the U.S. Food and Drug Administration (FDA) has cleared its CONTOUR® Next EZ, a new blood glucose monitoring (BGM) system for use in the United States. CONTOUR Next EZ includes an easy-to-use meter and test strip sensors with innovative technology for advanced accuracy. Bayer's new BGM system is being introduced on a market-by-market basis and is currently available in other countries as CONTOUR XT. In the U.S., CONTOUR Next EZ will be available this summer.
With Bayer's proprietary new blood glucose sensor technology, the CONTOUR Next EZ system delivers advanced accuracy that notably exceeds the requirements of ISO 15197:2003. The proprietary electrochemical mediator and meter algorithm utilized in the CONTOUR Next EZ blood glucose monitoring system provides a stable, high signal-to-noise ratio that facilitates accurate determination of blood glucose readings, even at low blood glucose levels. The new technology also ensures that the system remains accurate under a wide range of storage conditions, corrects for common errors and is not affected by hematocrit or many common interfering substances in the blood (e.g. acetaminophen, vitamin C).
The new CONTOUR Next EZ system was tested in a number of studies,,,, around the globe in which it consistently showed excellent performance in the hands of healthcare providers as well as patients.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical pro